Sage Mountain Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Sage Mountain Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-686	Closed	-$530K	–	506
2025 Q4	$530K	Sell	686 -227	-25%	-$154K	0.03%	262
2025 Q3	$514K	Buy	+913	New	+$516K	0.03%	267
2025 Q2	–	Sell	-323	Closed	-$205K	–	539
2025 Q1	$205K	Sell	323 -101	-24%	-$69.5K	0.02%	373
2024 Q4	$302K	Buy	424 +14	+3%	+$11.7K	0.02%	294
2024 Q3	$431K	Buy	410 +34	+9%	+$37.8K	0.04%	224
2024 Q2	$396K	Buy	376 +72	+24%	+$69.8K	0.04%	208
2024 Q1	$293K	Buy	304 +36	+13%	+$34.2K	0.03%	244
2023 Q4	$235K	Sell	268 -4	-1%	-$3.29K	0.03%	236
2023 Q3	$224K	Buy	+272	New	+$214K	0.03%	228

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Sage Mountain Advisors's REGN Position: Q1 2026 in Review

Sage Mountain Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 686 shares — an estimated $530K sold.

Sage Mountain Advisors first reported a position in REGN in Q3 2023 and held it in 9 quarters. The position peaked at $530K in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Sage Mountain Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Sage Mountain Advisors sold 686 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $530K.
Sage Mountain Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2023 and held it in 9 quarters.
Sage Mountain Advisors's Regeneron Pharmaceuticals position peaked at $530K in Q4 2025.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Sage Mountain Advisors's 13F filing for Q1 2026, filed 11 May 2026.